Maxigesic® Rapid (ODT)
Acute pain
LaunchedCommercial
Key Facts
About AFT Pharmaceuticals
AFT Pharmaceuticals is a commercial-stage specialty pharma company with a significant presence in Australasia and growing operations in Asia. Its core business model involves licensing and marketing a wide range of pharmaceutical products, while its key growth driver is the global development and commercialization of its patented intravenous and oral analgesic, Maxigesic® (a fixed-dose combination of paracetamol/acetaminophen and ibuprofen). The company has successfully transitioned from a distributor to an innovator, with Maxigesic IV approved and launched in multiple countries and an extensive pipeline of line extensions.
View full company profileTherapeutic Areas
Other Acute pain Drugs
| Drug | Company | Phase |
|---|---|---|
| VX-548 | Vertex Pharmaceuticals | Phase 3 |
| Maxigesic® Oral Tablets | AFT Pharmaceuticals | Approved/Commercial |
| Maxigesic® Intranasal Formulation | AFT Pharmaceuticals | Pre-clinical |